All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss

Ozempic butt is the sagging or flattening of the buttocks from rapid GLP-1 weight loss. This guide explains why it happens, STEP trial lean mass data,...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss custom 2026 header image for GLP-1 Weight Loss
Custom header image for Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss

Ozempic butt is the sagging or flattening of the buttocks from rapid GLP-1 weight loss. This guide explains why it happens, STEP trial lean mass data,...

Short answer

Ozempic butt is the sagging or flattening of the buttocks from rapid GLP-1 weight loss. This guide explains why it happens, STEP trial lean mass data,...

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, peptide evidence quality, safety and contraindications

How to use it

Use this information to prepare sharper questions for a licensed provider.

"Ozempic butt" refers to the sagging or flattening of the buttocks that occurs during rapid weight loss on GLP-1 medications like semaglutide. It happens because the body loses both fat and lean mass during weight loss, and the gluteal region, which stores significant subcutaneous fat, is particularly affected.

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Key Takeaway

Up to 39% of weight lost on GLP-1 medications can come from lean mass, including muscle. Prevention requires adequate protein (1.2 to 1.6 g/kg/day) and resistance training at least 2 to 3 times per week. The condition is largely preventable and partially reversible with the right approach. Protein intake matters; see our best diet with GLP-1 plan.

What Is Ozempic Butt and Why Does It Happen?

"Ozempic butt" became a widely used term in 2023 and 2024 as millions of people started GLP-1 medications for weight loss. The term describes a visible change: the buttocks lose volume, sag, and can appear deflated or flat. Similar volume loss can occur in the face ("Ozempic face"), arms, and other areas where subcutaneous fat sits close to the skin surface. Facial volume loss follows the same pattern. See our Semaglutide Face Aging article.

Three things drive Ozempic butt. First, fat loss. GLP-1 medications cause systemic fat reduction, and the gluteal region stores a large amount of subcutaneous fat. When that fat disappears, the overlying skin has less volume to sit on. Second, muscle loss. Rapid weight loss on any restricted-calorie protocol tends to include muscle tissue, not only fat. Third, skin laxity. If weight loss happens quickly, the skin does not always contract to match the reduced volume, especially in people over 40 or those who have lost large amounts of weight [1]. This is part of the broader semaglutide muscle loss concern with GLP-1 medications.

This is not unique to semaglutide or GLP-1 medications. Any rapid weight loss, whether from surgery, caloric restriction, or medication, produces the same combination of fat loss, potential muscle loss, and skin laxity. GLP-1 drugs just made it more visible because so many people are losing weight on them at once.

How Much Muscle Do You Actually Lose on GLP-1 Medications?

The STEP 1 trial body composition data (measured by DEXA scan) showed that semaglutide-treated participants lost an average of 15.3 kg total. Of that, lean body mass decreased by 6.92 kg, representing about 45% of total weight lost. Fat mass decreased by 19.3% from baseline, while lean mass decreased by about 9.7% [2].

A 2024 systematic review across multiple GLP-1 trials confirmed that approximately 25 to 40% of total weight lost on these medications comes from lean mass rather than fat. The wide range depends on factors like baseline body composition, protein intake, physical activity level, and rate of weight loss [3].

For context, a "healthy" ratio during weight loss is generally considered to be about 75% fat and 25% lean mass. The STEP 1 data suggests that without intervention, GLP-1 weight loss can skew higher on lean mass loss than that target. This is where prevention strategies become important.

STEP 1 Body Composition Changes (68 Weeks)
Measurement Semaglutide Group Placebo Group
Total weight loss -15.3 kg (-14.9%) -2.6 kg (-2.4%)
Fat mass change -19.3% -4.2%
Lean mass change -9.7% (-6.92 kg) -1.8%
Visceral fat change -27.4% -4.8%
Lean mass as % of weight lost ~45% ~30%

Why Does the Butt Get Hit So Hard?

The gluteal region is particularly affected for anatomical reasons. The buttocks contain three muscles (gluteus maximus, medius, and minimus) covered by a thick layer of subcutaneous fat. In women especially, the gluteal fat pad is a primary fat storage site driven by estrogen-mediated fat distribution [1].

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →

When you lose fat systemically, the gluteal fat pad shrinks. The gluteus maximus is the largest muscle in the body, but many people do not use it well due to sedentary lifestyles. Without targeted resistance training, the gluteal muscles can atrophy during caloric deficit, compounding the volume loss from fat reduction.

The result is a double hit: less fat padding on top of a potentially weakened muscle underneath, covered by skin that has lost its structural support. This is why Ozempic butt looks different from simply being thin. It is volume loss combined with tissue laxity.

How Do You Prevent Muscle Loss on GLP-1 Medications?

Prevention requires two interventions that work together: adequate protein intake and resistance training. Neither one alone is sufficient. Both together can shift the ratio of weight loss significantly toward fat and away from muscle [4].

Protein Intake: 1.2 to 1.6 g/kg/day

The standard recommendation for people on GLP-1 medications is 1.2 to 1.6 grams of protein per kilogram of body weight per day. For a 180-pound (82 kg) person, that is 98 to 131 grams of protein daily. Some experts recommend the higher end of this range if you are performing regular resistance training [4].

This is challenging on GLP-1 medications because appetite suppression makes eating less appealing. Many people struggle to eat enough total calories, let alone hit protein targets. Protein shakes, Greek yogurt, cottage cheese, and lean meats are practical ways to increase protein intake without requiring large-volume meals. Spacing protein across 3 to 4 meals (25 to 40 grams per meal) is more effective for muscle protein synthesis than eating it all at once [5].

Resistance Training: 2 to 4 Sessions Per Week

Resistance training sends a signal to your body that muscle tissue is needed. Without that signal during caloric deficit, the body treats muscle as expendable and breaks it down for energy. With regular strength training, the body preferentially preserves muscle and burns more fat [4].

A 2023 study found that participants who combined resistance training with high protein intake while on GLP-1 medications retained about 80 to 85% of their weight loss as fat, compared to only 60% in the sedentary group. That is a meaningful difference in body composition outcomes [6].

For the glutes specifically, compound movements like squats, deadlifts, hip thrusts, and lunges are the most effective. These exercises load the gluteal muscles heavily and provide the strongest stimulus for muscle preservation and growth. Glute bridges and hip thrusts directly target the gluteus maximus. Two to four sessions per week, progressively increasing weight over time, is the minimum effective dose. Resistance training is critical; see our best exercises on GLP-1 recommendations.

Slower Dose Titration

Faster weight loss tends to include more muscle loss. Working with your provider to titrate semaglutide doses more slowly (spending longer at each dose level before increasing) can reduce the rate of weight loss and give muscle tissue more time to adapt. The standard titration schedule moves up every 4 weeks, but some providers extend this to 6 or 8 weeks per step based on individual response [4].

Is Ozempic Butt Reversible?

Partially, yes. The muscle component is reversible through resistance training. You can build gluteal muscle even after losing it, though it takes consistent effort over months. Progressive overload on hip-dominant exercises (hip thrusts, Romanian deadlifts, step-ups) can add meaningful volume back to the glutes.

The fat component is trickier. You cannot spot-reduce or spot-regain fat in specific areas. If you stop GLP-1 medication and regain weight, fat will redistribute according to your body's normal pattern, which may or may not restore gluteal volume. Maintaining weight loss while adding muscle through training is the preferred approach.

Skin laxity is the hardest component to reverse without procedures. For mild cases, skin may gradually tighten over 12 to 24 months after weight stabilization. For significant skin excess, surgical options like a lower body lift or gluteal augmentation exist, but these are major procedures with real recovery time and risks.

SEMAGLUTIDE patients at FormBlends work with providers who can help design a protocol that minimizes muscle loss from the start, which is easier than trying to reverse it later.

What About Peptide Stacks for Muscle Preservation?

Some clinics offer peptide protocols alongside GLP-1 medications to help preserve lean mass. Growth hormone secretagogues like CJC-1295 and ipamorelin stimulate natural growth hormone release, which can support muscle maintenance during caloric deficit. These are not FDA-approved for this use and the evidence base is smaller than for protein and resistance training [7].

The fundamentals (protein and strength training) should always come first. Peptide protocols may offer additional support for some patients, but they are not a substitute for eating enough protein and lifting weights. peptide therapy

Frequently Asked Questions

How common is Ozempic butt?

Some degree of gluteal volume loss occurs in most people who lose significant weight on GLP-1 medications. It is more noticeable in people who lose 15% or more of body weight, do not resistance train, and do not eat adequate protein. It is less common in people who combine medication with strength training.

Can you prevent Ozempic butt completely?

You can significantly reduce it. High protein intake (1.2 to 1.6 g/kg/day) and resistance training 2 to 4 times per week can shift weight loss composition to 80-85% fat instead of 55-60%. You will still lose some gluteal fat, but muscle preservation fills much of the gap.

Does Ozempic butt happen with tirzepatide too?

Yes. Any medication that causes significant weight loss can produce similar body composition changes. Tirzepatide (Mounjaro/Zepbound) often produces greater total weight loss than semaglutide, so the same muscle preservation strategies are equally important.

How much protein should I eat on semaglutide?

Aim for 1.2 to 1.6 grams per kilogram of body weight daily. For a 180-pound person, that is about 100 to 130 grams of protein per day. Spread it across 3 to 4 meals for best results. Protein shakes can help when appetite is low.

Can you build glute muscle while on Ozempic?

Yes, though building new muscle is harder during caloric deficit than preserving existing muscle. With adequate protein and progressive resistance training (hip thrusts, squats, deadlifts), you can maintain and even build gluteal muscle while losing fat on GLP-1 medication.

Does Ozempic face happen for the same reason?

Yes. "Ozempic face" is volume loss in the face from reduced subcutaneous fat, similar to what happens in the glutes. The face has less muscle to compensate, so volume loss is often more visible there. Dermal fillers are sometimes used to restore facial volume after significant weight loss.

Should I slow down my semaglutide dose to prevent muscle loss?

Slower dose titration can help by reducing the rate of weight loss. Discuss this with your provider. Spending more time at each dose level (6 to 8 weeks instead of 4) allows your body more time to adapt. Protein intake and resistance training are still the most important factors.


Medical References

  1. California Trim Clinic. Ozempic Butt Explained: How CJC-1295/Ipamorelin Helps Preserve Glute Muscle During GLP-1 Weight Loss. CaliforniaTrimClinic.com. Accessed April 2026.
  2. Batterham RL, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Diabetes Obes Metab. 2024. PMC8089287
  3. Sargeant JA, et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Obes Rev. 2024;25(7):e13714. PMID: 38629387
  4. Potere Health MD. Prevent Muscle Loss on Zepbound & Ozempic: MD Strategies. PotereHealthMD.com. Accessed April 2026.
  5. Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(8):2842-2853. PMID: 38839060
  6. Hinge Health. Ozempic and Exercise: How to Maintain Muscle on a GLP-1. HingeHealth.com. Accessed April 2026.
  7. Highbar Health. GLP-1 Drugs and Muscle Loss: What Patients Need to Know. HighbarHealth.com. Accessed April 2026.

This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any medication or protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.

Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-07-02T16:33:54Z
FormBlends review
FormBlends official source
Official source
Found official source
Official source
Maximus Tribe official source
Official source
Ozempic evidence source
Official source
Semaglutide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-07-02T16:33:54Z.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Ozempic butt is the sagging or flattening of the buttocks from rapid GLP-1 weight loss. This guide explains why it happens, STEP trial lean mass data, prevention with protein and resistance training, and when the changes are reversible. "Ozempic Butt: Why GLP-1 Weight Loss Causes Muscle and Volume Loss" works best as a practical checklist for the next conversation. It focuses on patient education and clinical context, then narrows the issue through semaglutide. With 7 sections, the FAQ can reveal what readers usually miss. Use the page to prepare, then verify the personal medical pieces with a licensed clinician.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Ozempic Butt

For this glp-1 weight loss page, the 2026 refresh focuses on semaglutide, tirzepatide, ozempic, butt, muscle, loss so the article stays close to the question behind "Ozempic Butt".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Ozempic Butt from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Ozempic Butt custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Ozempic Butt, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Ozempic Butt, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.